NIH Funding — $1.2 Billion at Risk

Philadelphia received [over $1.1 billion in NIH funding in 2024](https://economyleague.org/) — the canonical figure from the Economy League of Greater Philadelphia, which puts the city total at roughly $1.1B to $1.3B depending on whether you count the metro or the city proper. Call it $1.2B for round numbers. That figure is larger than the individual budgets of most city agencies. It funds researchers at Penn, at CHOP, at Temple, at Jefferson. It pays salaries. It buys equipment. It pays for the clinical trials that bring experimental treatments to actual patients. It is, in a very concrete sense, the economic foundation on which Philadelphia’s identity as a research city was built.

Now consider what happens when that number faces a federal budget cycle that has already shown itself willing to make sweeping cuts without warning. The clearest case is the [February 2025 NIH directive capping indirect cost reimbursement at 15%](https://www.inquirer.com/health/philadelphia-penn-trump-nih-funding-cuts-research-20250211.html) — a single federal action that Penn said would cost the university [nearly $250 million per year](https://www.healio.com/news/hematology-oncology/20250210/penn-research-could-lose-nearly-250m-under-trump-administrations-nih-funding-cuts). The Daily Pennsylvanian put the figure slightly lower, at [$240 million based on the FY2026 budget projection](https://www.thedp.com/article/2025/03/penn-faces-uncertain-future-amidst-federal-funding-cuts). That is Penn specifically. It does not include CHOP, Temple, Jefferson, or the smaller research institutions scattered throughout the region.

$250 million per year is not a line item. It is a category of loss that cascades through an institution. Graduate student positions disappear. Postdocs lose their fellowships. Lab equipment purchases get deferred. Senior researchers who built their careers around a specific funding stream find themselves adrift. The people who were in the middle of a five-year study discover that the study can no longer be funded, and the data they collected becomes orphaned.

Philadelphia's economic identity is built on this. Not manufacturing. Not finance, really. Research. The institutions that anchor University City, that employ thousands of highly educated workers, that attract companies looking to tap into a research ecosystem — all of it depends on a flow of federal research dollars that a single budget cycle could severely disrupt.

This is not an abstract policy concern. It is a question about what Philadelphia becomes if the research institutions contract. If Penn loses 250 million annually, it does not simply absorb the loss gracefully. It cuts programs. It reduces faculty. It scales back expansion plans. The companies that located near Penn's research facilities to take advantage of proximity to scientists and clinicians begin to reconsider.

Philadelphia’s response to this vulnerability has been muted. There have been statements from institutional leaders. There has been lobbying. But the fundamental issue is that the city built its economic identity on a foundation that depends almost entirely on the continued goodwill of a federal government that has shown it can change course rapidly and without regard for local consequences.

And the city’s own balance sheet is not reassuring on this front either. The Controller’s office found that Philadelphia was closing its roughly $4.4 billion Comprehensive Annual Financial Report in Lotus 1-2-3 spreadsheets with no role-based access controls. A research economy that depends on federal goodwill is fragile enough; pairing it with a city whose books cannot even distinguish a data-entry error from a deliberate withdrawal is a structural risk that compounds the funding exposure.

Philadelphia survives without NIH funding. That's not the question. The question is what Philadelphia becomes when the research institutions contract—when programs shut down, when companies relocate to cities where the ecosystem remained intact. That identity was built over decades. A single budget cycle could diminish it.

Notes, Sources, and Methodology

The $1.1B-$1.3B Philadelphia NIH total for FY2024 is from the [Economy League of Greater Philadelphia’s Life Sciences Industry report](https://economyleague.org/), which puts the figure at "over $1.1 billion" for Philadelphia institutions; CBRE and JLL both round to "almost $1.3 billion" for the Philadelphia region. Underlying award-level data by institution is available through [NIH RePORTER](https://report.nih.gov/award/), the federal database of NIH-funded projects. CHOP alone received $152.9M across 309 NIH grants in FY2024 (ranked #60 nationally).

The $250M Penn figure refers specifically to the [February 2025 NIH directive capping indirect cost reimbursement at 15%](https://www.inquirer.com/health/philadelphia-penn-trump-nih-funding-cuts-research-20250211.html), not the broader FY2026 budget proposal. Penn’s own statement to the press was that the directive would cost the university [nearly $250 million per year](https://www.healio.com/news/hematology-oncology/20250210/penn-research-could-lose-nearly-250m-under-trump-administrations-nih-funding-cuts); [City & State PA](https://www.cityandstatepa.com/) reported the same figure. [The Daily Pennsylvanian](https://www.thedp.com/) put the number slightly lower, at $240M, based on the FY2026 budget projection — the lower bound of the estimate. The Feb 2025 directive was challenged in federal court in spring 2025; the legal status of the cap was unresolved through 2026.

The reporting on Penn’s response — faculty ordered to halt $175M in research, a plan to reduce graduate admissions by a third, the Perelman School of Medicine facing a separate $140M exposure — comes from [WHYY (Mar 25, 2025)](https://whyy.org/) and the [Philadelphia Inquirer (Feb 28, 2025)](https://www.inquirer.com/). The "at risk" framing in this article’s title refers to the proposed and contested federal actions, not to realized cuts; as of mid-2026, no institution in Philadelphia has reported an actual $1.2B aggregate loss.